Johnson & Johnson to present new neuropsychiatry data across 24 studies at Psych Congress 2026

Johnson & Johnson is set to present 24 abstracts covering clinical findings and real world evidence from across its neuropsychiatry portfolio at the 2026 Psych Congress Annual Meeting, taking place from September 15 to 19 in New Orleans.

The research will include pivotal Phase 3 findings for CAPLYTA, or lumateperone, in adults with bipolar mania. Further studies involving CAPLYTA in bipolar depression and major depressive disorder will also be presented, adding to the evidence being generated across a range of mood disorders.

Additional analyses will focus on SPRAVATO, or esketamine nasal spray, including research examining its effects on depressive symptoms such as anhedonia.

Johnson & Johnson will also share Phase 3 clinical trial findings for seltorexant in patients with major depressive disorder who experience symptoms of insomnia.

Together, the planned presentations cover several areas in which patients and clinicians continue to face challenges with diagnosis, treatment selection and long term disease management.

Jane Tiller, Vice President and Global Head of Development for Neuroscience at Johnson & Johnson, said people living with neuropsychiatric conditions can experience complicated and overlapping symptoms that make both treatment and ongoing management more difficult.

She added that the company is continuing to develop clinical and real world evidence across both its existing portfolio and pipeline, with the aim of supporting more informed treatment decisions in psychiatric care.

The data being presented at Psych Congress 2026 will span bipolar mania, bipolar depression, major depressive disorder and schizophrenia, reflecting Johnson & Johnson’s broader focus on developing therapies for complex neuropsychiatric conditions with significant unmet treatment needs.

---

---

Related Topics and Keywords

bipolar disorder, caplyta, depression, Johnson and Johnson, mental health, pharma news, PsychCongress2026, schizophrenia, SPRAVATO® (esketamine)